The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism

Kidney International

Volumn 63, Issue 1, 2003, Pages 248-254

  Lindberg, Jill S ^{a,b,c,d,e,f,g}   Moe, Sharon M ^{a,b,c,d,e,f,g}   Goodman, William G ^{a,b,c,d,e,f,g}   Coburn, Jack W ^{a,b,c,d,e,f,g}   Sprague, Stuart M ^{a,b,c,d,e,f,g}   Liu, Wei ^{a,b,c,d,e,f,g}   Blaisdell, Peter W ^{a,b,c,d,e,f,g}   Brenner, Robert M ^{a,b,c,d,e,f,g}   Turner, Stewart A ^{a,b,c,d,e,f,g}   Martin, Kevin J ^{a,b,c,d,e,f,g}  

^a OCHSNER MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e EVANSTON HOSPITAL   (United States)

^f AMGEN INC   (United States)

^g SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Calcimimetic; Calcium x phosphorus; Calcium sensing receptor; End stage renal disease; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

CALCIUM; CALCIUM CHANNEL STIMULATING AGENT; CINACALCET; PARATHYROID HORMONE; PHOSPHORUS; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM;

EID: 6444245707     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00720.x     Document Type: Article

References (26)

1. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int 56(Suppl 73):S14-S19, 1999
2. Massry SG, Coburn JW, Popovtzer MM, et al: Secondary hyperparathyroidism in chronic renal failure. Arch Intern Med 124:431-441, 1969
3. Massry SG, Smogorzewski M: Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14:219-231, 1994
4. Rostand SG, Drucke TB: Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56:383-392, 1999
5. bro S, olgaard K: Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 30:606-620, 1997
6. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617, 1998
7. Cundy T, Hand DJ, Oliver DO, et al: Who gets renal bone disease before beginning dialysis? Br Med J 290:271-275, 1985
8. Sherrard DJ, Hercz G, Pei Y, et al: The spectrum of bone disease in end stage renal failure - An evolving disorder. Kidney Int 43:436-442, 1993
9. Andress DL, Norris kc, Coburn JW, et al: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274-279, 1989
10. Salusky IB, Kuizon BD, Belin TR: Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54:907-914, 1998
11. Martin KJ, Gonzalez EA, Gellens M, et al: 19-Nor-1-α-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of PTH in patients with hemodialysis. J Am Soc Nephrol 9:1427-1432, 1998
12. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187-1201, 2001
13. Chertow GM, Burke SK, Lazarus JM, et al: Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 29:66-71, 1997
14. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 29:641-649, 1997
15. Cunningham J: What is the optimal regimen for vitamin D? Kidney Int 56(Suppl 73):S59-S64, 1999
16. Block GA, Port FK: Re-evaluation of risks associated with hyperphophatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 35:1226-1237, 2000
17. Hammerland LG, Garrett JE, Hung BCP, et al: Allosteric activation of the calcium receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. Mol Pharmacol 53:1083-1088, 1998
18. Nemeth EF, Steffey ME, Hammerland LG, et al: Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95:4040-4045, 1998
19. Nemeth EF: Calcium receptors as novel drug targets, in Principles in Bone Biology, edited by BILEZIKIAN JP, RAISZ LG, RODAN GA, San Diego, Academic Press, Inc., 1996, pp1019-1035
20. Goodman WG, Hladik GA, Turner SA, et al: The calcimimetic agent AMG 073 lowers parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 13:1017-1024, 2002
21. Chertow GM, Plone M, Dillon MA, et al: Hyperparathyroidism and dialysis vintage. Clin Nephrol 54:295-300, 2000
22. Ganesh SK, Stack AG, Levin N, et al: Association of elevated serum phosphorus, calcium x phosphorus product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131-2138, 2001
23. Llach F: Hyperphosphatemia in end-stage renal disease patients: Pathophysiological consenquences. Kidney Int 56(Suppl 73):S31-S37, 1999
24. Goodman WG, Goldin J, Kuizon BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
25. Juppner H, Brown EM, Kronenberg HM: Parathyroid hormone, in Metabolic Bone Diseases and Disorders of Mineral Metabolism, 4th Ed., edited by FAVUS MJ, Philadelphia, Lippincott Williams & Wilkins, 1999, pp 81-87
26. Yamaguchi T, Chattopadhyay N, Kifor O, et al: Expression of extracellular calcium sensing receptor in human osteoblastic MG-63 cell line. Am J Cell Physiol 280:382-393, 2001